ICUI Stock Summary and Trading Ideas (Icu Medical | NASDAQ:ICUI)

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Icu Medical trades on the NASDAQ stock market under the symbol ICUI.

As of March 6, 2026, ICUI stock price declined to $132.00 with 174,472 million shares trading.

ICUI has a beta of 0.70, meaning it tends to be less sensitive to market movements. ICUI has a correlation of 0.09 to the broad based SPY ETF.

ICUI has a market cap of $3.26 billion. This is considered a Mid Cap stock.

Last quarter Icu Medical reported $541 million in Revenue and $1.91 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.37.

In the last 3 years, ICUI traded as high as $212.43 and as low as $78.28.

The top ETF exchange traded funds that ICUI belongs to (by Net Assets): IJR, VTI, VB, IWM, VBR.

ICUI has underperformed the market in the last year with a price return of -7.2% while the SPY ETF gained +18.7%. ICUI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.4% and -15.9%, respectively, while the SPY returned -1.7% and -2.5%, respectively.

ICUI support price is $133.02 and resistance is $140.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICUI shares will trade within this expected range on the day.